1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Head and neck cancers

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

Technology appraisal guidance [TA661] Published date: 25 November 2020

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Documents

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 158.2 KB 25 November 2020  

Final appraisal document: 2

  • Final appraisal document: 2  
  • Committee papers PDF 2.36 MB 22 October 2020  
  • Public committee slides PDF 1.02 MB 22 October 2020  
  • Final appraisal document 2 PDF 281.37 KB 22 October 2020  

Appraisal consultation

  • Appraisal consultation  
  • Appraisal consultation document (PDF version) PDF 304.7 KB 15 January 2020  
  • Committee papers PDF 8.81 MB 15 January 2020  
  • Public committee slides PDF 1.33 MB 15 January 2020  
  • Appraisal consultation document (online commenting)  

Invitation to participate

  • Final scope PDF 183.07 KB 21 March 2019  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 203.81 KB 21 March 2019  
  • Equality impact assessment (Scoping) PDF 122.22 KB 21 March 2019  
  • Final stakeholder list PDF 186.89 KB 21 March 2019  

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators  
  • Draft scope post referral PDF 330.14 KB 19 July 2017  
  • Draft matrix post referral PDF 260.04 KB 19 July 2017